Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

In a report released today, Emily Field from Barclays maintained a Buy rating on Genmab A/S (0MGB – Research Report), with a price target of ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...

Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...

Investing.com -- Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates. The ...

Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...

Investing.com -- Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates.

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...

Truist Securities reiterated their Buy rating on Genmab A/S (NASDAQ:GMAB) with a steady price target of $50.00. The firm's analysts remain confident in the biotech company's prospects, particularly in ...